This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/the-biotech-resurgence"
},
"headline": "The Biotech Resurgence",
"description": "This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2024-03-07"
}
</script>
Actions
Pages
Subscribe for newsletter
Stories
Sage Therapeutics and Biogen have introduced Zurzuvae, the first oral medication designed specifically for the treatment of postpartum depression (PPD).
With an estimated 500,000 new mothers in the U.S. alone facing PPD annually, the need for accessible, effective treatment options has never been more urgent. Zurzuvae's entry into the market is a testament to the evolving understanding and commitment to addressing maternal mental health with the seriousness it deserves.
Barry Greene, CEO of Sage Therapeutics, expressed optimism about Zurzuvae's market potential, stating, "It’s early but I do believe that Zurzuvae is the key to unlock the blockbuster potential of PPD, enabling us to help many women suffering from postpartum depression."
As Zurzuvae's market presence grows, its long-term impact on the treatment landscape for postpartum depression will be closely watched. The ongoing efforts by Sage and Biogen to ensure insurance coverage and to destigmatize PPD are crucial steps toward making Zurzuvae a staple in postnatal care. Furthermore, the companies' commitment to expanding treatment accessibility through a specialty pharmacy distribution network indicates a future where support for maternal mental health is both readily available and widely accepted.
Zurzuvae's mechanism, targeting the GABA-A receptors in the brain, offers a novel approach to PPD treatment, distinguishing it from traditional antidepressants. This scientific breakthrough provides a new lens through which to view and address the complexities of postpartum depression.
Story
British satellite operator Avanti Communications has joined forces with Canadian satellite communications company Telesat. This partnership is set to integrate the forthcoming low Earth orbit (LEO) services of Telesat's Lightspeed constellation with Avanti's extensive geostationary network, offering connectivity solutions to enterprise and government sectors across Europe, the Middle East, and Africa.
This collaboration aims to meet escalating demand for high-speed, reliable internet access worldwide, driven by the digital transformation of economies and the increasing reliance on cloud-based and IoT technologies. The integration of multi-orbit satellite networks combine the wide reach and high capacity of geostationary satellites with the low latency and agility of LEO constellations. This synergy is poised to unlock new possibilities in telecommunications, remote sensing, and digital inclusion, setting a new benchmark for global connectivity.
Avanti CEO Kyle Whitehill emphasized the transformative potential of this partnership: "Integrating Telesat's Lightspeed services into our network aligns perfectly with our vision to offer cutting-edge, multi-orbit connectivity solutions that meet the evolving needs of our customers."
As the space industry looks forward to the operationalization of the Telesat Lightspeed constellation in 2027, this partnership is a glimpse into the future of global broadband services. It will Enhance broadband capacity and reduce latency for high-demand areas and critical connectivity for remote and underserved regions.
The collaboration between Avanti and Telesat is a testament to the dynamic nature of the satellite communications industry, which is increasingly characterized by strategic alliances and technological innovation.
Telesat has partnered with SpaceX for 14 launches of its satellites using the Falcon 9 rocket, aiming for efficient deployment into orbit.
Telesat's Lightspeed satellites, positioned closer to Earth, are designed to offer lower latency, enhancing wireless service for remote areas and mobile applications. Targeting enterprise customers, Telesat positions itself as a competitor in the space-based communications market, differentiating from direct-to-consumer services like SpaceX’s Starlink.
Story
A recent survey by global investment firm KKR highlights a significant pivot among family offices towards private equity investments, driven by a search for stable, long-term returns.
Family offices are making a strategic pivot towards private equity, drawn by the promise of long-term, sustainable returns. This alignment with private markets fund managers on investment timelines further solidifies the trend. It reflects a cautious approach in a volatile market, emphasizing the importance of return on and return of capital.
The current fundraising environment in private markets is described as challenging, with the process now taking an average of 22 months, a substantial increase from the nine months seen during the COVID period. This has led family offices to be more selective, gravitating towards established, top-quartile brand names for growth and buyouts.
Despite the tough fundraising climate, emerging fund managers with a solid track record, even if brief, have opportunities. Notably, those with high-impact exits (returns of four to four and a half times investment) can attract attention from family offices.
Despite a current preference for private equity, there are indications of long-term interest in venture capital from family offices. This interest is part of a broader trend of increasing allocations to the private equity bucket, which includes buyouts, growth stage investments, and venture capital, with some family offices moving into double-digit allocations to venture capital.
Story
Innovators
Scroll
Open
Close